In Q3 2022, Foresite Capital held 3 positions worth $26.5M. They initiated 3 new positions. Their largest holding was ASND ($13.8M).
Frequently asked questions
What stocks did Foresite Capital own in Q3 2022?
Foresite Capital held 3 biotech stocks in their 13F portfolio in Q3 2022. Their top positions include ASND, NTRA, CBAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Foresite Capital's portfolio worth in Q3 2022?
Foresite Capital's tracked biotech portfolio was worth $26.5M across 3 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Foresite Capital buy in Q3 2022?
Foresite Capital initiated 3 new positions in Q3 2022, including ASND, NTRA, CBAY. They also increased 0 existing positions.
What did Foresite Capital sell in Q3 2022?
Foresite Capital did not fully exit any positions in Q3 2022.
Is Foresite Capital a biotech fund?
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
Want AI analysis, insider signals, and catalyst overlays for Foresite Capital?
View latest Foresite Capitalportfolio →